Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2008 1
2009 1
2010 1
2013 1
2015 1
2018 2
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic factor in patient with recurrent pancreatic adenocarcinoma.
Sumiyoshi T, Uemura K, Shintakuya R, Okada K, Otsuka H, Baba K, Serikawa M, Ishii Y, Tsuboi T, Arihiro K, Murakami Y, Murashita J, Takahashi S. Sumiyoshi T, et al. Langenbecks Arch Surg. 2023 Sep 2;408(1):347. doi: 10.1007/s00423-023-03073-2. Langenbecks Arch Surg. 2023. PMID: 37658871
Multivariate analysis showed that red blood cell (RBC) transfusion (HR, 2.80; p = 0.0051), low albumin level (HR, 1.84; p = 0.0402), and high carbohydrate antigen 19-9 (CA19-9) level at recurrence (HR, 2.11; p = 0.0258) were significant predictors of shorter survival after …
Multivariate analysis showed that red blood cell (RBC) transfusion (HR, 2.80; p = 0.0051), low albumin level (HR, 1.84; p = 0.0402), and hig …
Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy.
Makita K, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Takimoto R, Goto S. Makita K, et al. Anticancer Res. 2018 Jul;38(7):4353-4360. doi: 10.21873/anticanres.12736. Anticancer Res. 2018. PMID: 29970573
BACKGROUND/AIM: The past 17 years, immune-cell therapy has been administered to 990 patients with advanced or recurrent pancreatic adenocarcinoma and 50 patients with curatively resected pancreatic adenocarcinoma. ...RESULTS: The median OS of advanced or recu …
BACKGROUND/AIM: The past 17 years, immune-cell therapy has been administered to 990 patients with advanced or recurrent pancreatic …
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma.
Yang SH, Lu LC, Kao HF, Chen BB, Kuo TC, Kuo SH, Tien YW, Bai LY, Cheng AL, Yeh KH. Yang SH, et al. Oncoimmunology. 2021 Sep 27;10(1):1973710. doi: 10.1080/2162402X.2021.1973710. eCollection 2021. Oncoimmunology. 2021. PMID: 34595057 Free PMC article.
In the control groups of patients receiving gemcitabine-based chemotherapy (n = 142) or FOLFIRINOX regimen (n = 24), spleen volume exhibited no prognostic significance. In heavily pretreated PDAC, a large spleen may predict poor OS following nivolumab-based immunotherapy. …
In the control groups of patients receiving gemcitabine-based chemotherapy (n = 142) or FOLFIRINOX regimen (n = 24), spleen volume exhibited …
Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S, Balachandran A, Katz M, Reddy A, Rohren E, Bhosale P. Rayamajhi S, et al. Abdom Radiol (NY). 2018 Feb;43(2):505-513. doi: 10.1007/s00261-017-1316-z. Abdom Radiol (NY). 2018. PMID: 28900703
We evaluated the utility of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and contrast-enhanced computed tomography (CECT) in the diagnosis of recurrent pancreatic adenocarcinoma in conjunction with the tumor marke …
We evaluated the utility of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and contrast-enhanced …
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.
Tozzi A, Comito T, Alongi F, Navarria P, Iftode C, Mancosu P, Reggiori G, Clerici E, Rimassa L, Zerbi A, Fogliata A, Cozzi L, Tomatis S, Scorsetti M. Tozzi A, et al. Radiat Oncol. 2013 Jun 21;8:148. doi: 10.1186/1748-717X-8-148. Radiat Oncol. 2013. PMID: 23799996 Free PMC article.
METHODS: Between January 2010 and October 2011, 30 patients with unresectable or recurrent pancreatic adenocarcinoma underwent exclusive SBRT. Twenty-one patients (70%) presented with unresectable locally advanced disease and 9 patients (30%) showed local rec …
METHODS: Between January 2010 and October 2011, 30 patients with unresectable or recurrent pancreatic adenocarcinoma un …
18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD. Rose DM, et al. Ann Surg. 1999 May;229(5):729-37; discussion 737-8. doi: 10.1097/00000658-199905000-00016. Ann Surg. 1999. PMID: 10235532 Free PMC article. Review.
OBJECTIVE: To assess the accuracy and clinical impact of 18fluorodeoxyglucose-positron emission tomography (18FDG-PET) on the management of patients with suspected primary or recurrent pancreatic adenocarcinoma, and to assess the utility of 18FDG-PET in gradi …
OBJECTIVE: To assess the accuracy and clinical impact of 18fluorodeoxyglucose-positron emission tomography (18FDG-PET) on the management of …
Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.
Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, Muzikansky A, Zhu AX. Goulart BH, et al. J Hematol Oncol. 2009 Mar 16;2:13. doi: 10.1186/1756-8722-2-13. J Hematol Oncol. 2009. PMID: 19291303 Free PMC article.
We analyzed the survival outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival durations. METHODS: We identified 20 patients with metastatic or recurrent pancreatic adenocarcinoma who received single-agent gemcit …
We analyzed the survival outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival durations. MET …
Pancreaticoduodenectomy with Reconstruction of the Mesentericoportal Vein by the Parietal Peritoneum: 'Safi Dokmak Vascular Graft'.
Dokmak S. Dokmak S. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S343-4. doi: 10.1245/s10434-015-4635-8. Epub 2015 Jul 7. Ann Surg Oncol. 2015. PMID: 26148755
All data were collected prospectively and complications were recorded according to the Clavien-Dindo classification.5 Our experience is illustrated in a patient who underwent pancreaticoduodenectomy with reconstruction of the MPV, using the PP, for recurrent pancreatic …
All data were collected prospectively and complications were recorded according to the Clavien-Dindo classification.5 Our experience is illu …
Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients.
Didolkar MS, Coleman CW, Brenner MJ, Chu KU, Olexa N, Stanwyck E, Yu A, Neerchal N, Rabinowitz S. Didolkar MS, et al. J Gastrointest Surg. 2010 Oct;14(10):1547-59. doi: 10.1007/s11605-010-1323-7. Epub 2010 Sep 14. J Gastrointest Surg. 2010. PMID: 20839073
We treated 85 consecutive patients with locally advanced and recurrent pancreatic adenocarcinoma from February 2004 to November 2009. ...RESULTS: Tumor control: complete, partial, and stable disease were observed in 78 patients for the duration of 3-36 …
We treated 85 consecutive patients with locally advanced and recurrent pancreatic adenocarcinoma from February 2004 to …
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V. Reni M, et al. Am J Clin Oncol. 2008 Apr;31(2):145-50. doi: 10.1097/COC.0b013e31814688f7. Am J Clin Oncol. 2008. PMID: 18391598 Clinical Trial.
The activity and safety of this combination regimen were assessed by means of an observational study in a population of patients with progressive or recurrent pancreatic adenocarcinoma after gemcitabine-containing chemotherapy. ...Main grade >2 toxi …
The activity and safety of this combination regimen were assessed by means of an observational study in a population of patients with …